Mr. Ajiashvili is described as “very client-friendly, dependable, thoughtful and thorough."
Chambers USA 2019

Nathan Ajiashvili

New York
  • 885 Third Avenue
  • New York, NY 10022-4834
  • USA
 
 

Nathan Ajiashvili is a partner in the New York office of Latham & Watkins. Mr. Ajiashvili is a member of the Corporate Department and Capital Markets, Private Equity Finance, and Public Company Representation Practices.

Mr. Ajiashvili represents both financial institutions and issuers engaging in equity and debt capital markets transactions in a broad array of industries, including life sciences, pharmaceuticals, technology, retail and consumer products, hospitality, gaming, defense, and automotive. Mr. Ajiashvili has experience in a range of financing transactions, including initial public offerings, high yield debt offerings, public and private equity offerings, leveraged buyouts, debt exchange offers, tender offers, and consent solicitations.

Mr. Ajiashvili also represents domestic and foreign companies regarding general corporate and securities matters, including corporate governance issues, public company reporting obligations, and stock exchange rules and requirements.

Mr. Ajiashvili currently serves on the firm’s Strategic Client Committee. Chambers USA 2019 has recognized Mr. Ajiashvili as an Up and Coming lawyer and the New York Super Lawyers has selected Mr. Ajiashvili as a Rising Star since 2013 in the area of Securities & Corporate Finance. Mr. Ajiashvili is also recommended for Capital Markets: Equity Offerings by The Legal 500 US 2016.

Mr. Ajiashvili’s representative IPO experience includes advising:

  • Precision BioSciences in connection with its IPO
  • Bank of America Merrill Lynch and JP Morgan in connection with the IPO of Avedro
  • Kiniksa Pharmaceuticals in connection with its IPO
  • Inspire Medical Systems in connection with its IPO
  • Sol-Gel Technologies in connection with its IPO
  • Bank of America Merrill Lynch in connection with the IPO of resTORbio
  • Bank of America Merrill Lynch in connection with the IPO of Spero Therapeutics
  • Verona Pharma in connection with its dual listing on the Nasdaq
  • JP Morgan and Morgan Stanley in connection with the IPO of Acushnet Holdings
  • Citigroup in connection with the IPO of Myovant Sciences
  • Merus in connection with its IPO
  • Bank of America Merrill Lynch in connection with the IPO of American Renal Associates
  • Jefferies in connection with the IPO of Aclaris Therapeutics
  • Jefferies in connection with the IPO of Axovant Sciences
  • Piper Jaffray in connection with the IPO of CoLucid Pharmaceuticals
  • Press Ganey in connection with its IPO   
  • Bank of America Merrill Lynch in connection with the IPO of Metaldyne Performance    

Mr. Ajiashvili’s representative high yield debt transactions include advising:

  • Barclays in connection with the senior notes offerings by PVH
  • The initial purchasers in connection with the senior notes offerings by Icahn Enterprises
  • Goldman Sachs in connection with the senior secured notes offerings by ContourGlobal
  • Deutsche Bank in connection with the offerings of senior secured notes and senior notes by Federal Mogul
  • Bank of America Merrill Lynch in connection with the senior notes offerings by SNF
  • Goldman Sachs in connection with the senior secured notes offering by Peabody Energy to fund its emergence from Chapter 11
  • Barclays in connection with the senior notes offerings by ACCO Brands
  • Goldman Sachs in connection with the senior secured notes offering by Rivers Casino
  • Wells Fargo in connection with the senior notes offering by First Quality        
  • Credit Suisse in connection with the senior secured notes offerings by Harland Clarke
  • Bank of America Merrill Lynch in connection with the senior notes offering by Transfield Services
  • Neuberger Berman in connection with its offering of senior notes
Thought Leadership
  • The Latham US IPO Guide
  • 10 Rules for Public Companies When Giving Guidance
  • Giving Good Guidance on Earnings
  • Giving Good Guidance: What Every Public Company Should Know
 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.